Q-omics provides the consensus-scored BTF3P5 profile across patient tissues and cancer cell-line models. BTF3P5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, BTF3P5 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, BTF3P5 RNA expression shows 10,275 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, COAD, and ACC as cancer lineages where BTF3P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTF3P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTF3P5 survival associations across molecular data types. BTF3P5 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTF3P5 RNA expression–survival associations across cancer types. High BTF3P5 expression shows unfavorable associations in KICH, LIHC and UCS, but favorable associations in CESC, KIRC and COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for BTF3P5 RNA expression.
This table summarizes BTF3P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BTF3P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTF3P5 shows higher tumor expression in COAD, KIRC, LUAD, BLCA, LUSC and PRAD. The COAD box plot shows higher BTF3P5 RNA expression in tumor versus normal tissue (log2 FC = +0.515, t-test p < 0.001).
This table shows molecular features associated with BTF3P5 in patient tissues and cancer cell lines. In patient samples, BTF3P5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
